During the past decade, Saitama Medical University International Medical Center conducted 70 clinical trials. In the 10-year time frame, 70 clinical trials started and 34 clinical trials were completed, i.e. on average, 48.6% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 26 clinical trials were completed. i.e. 78.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saitama Medical University International Medical Center" #1 sponsor was "National Cancer Institute (NCI)" with 9 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Incyte Corporation" with 5 trials sponsored, "Daiichi Sankyo Co., Ltd." with 4 trials sponsored and "Pfizer" with 4 trials sponsored. Other sponsors include 61 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saitama Medical University International Medical Center" #1 collaborator was "NRG Oncology" with 8 trials as a collaborator, "National Cancer Institute (NCI)" with 6 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator and "Merck Sharp & Dohme LLC" with 3 trials as a collaborator. Other collaborators include 70 different institutions and companies that were collaborators in the rest 68 trials.

According to Clinical.Site data, the most researched conditions in "Saitama Medical University International Medical Center" are "Ovarian Cancer" (6 trials), "Fallopian Tube Cancer" (5 trials), "Fallopian Tube Clear Cell Adenocarcinoma" (4 trials), "Fallopian Tube Transitional Cell Carcinoma" (4 trials) and "Heart Failure" (4 trials). Many other conditions were trialed in "Saitama Medical University International Medical Center" in a lesser frequency.

Most popular intervention types in "Saitama Medical University International Medical Center" are "Drug" (75 trials), "Other" (17 trials), "Biological" (14 trials), "Procedure" (12 trials) and "Device" (9 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (12 trials), "Paclitaxel" (12 trials), "Placebo" (12 trials), "Pembrolizumab" (8 trials) and "Quality-of-Life Assessment" (8 trials). Other intervention names were less common.

The vast majority of trials in "Saitama Medical University International Medical Center" are 62 trials for "All" genders, 30 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Saitama Medical University International Medical Center". undefined are not yet recruiting, 23 are recruiting, 32 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Saitama Medical University International Medical Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Saitama Medical University International Medical Center, 8 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 50 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 11 trials that are defined as “Not Applicable".